New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 2, 2013
05:55 EDTGLW, GLW, GSK, GSK, PFE, PFE, BAYRY, BAYRY, LLY, LLY, SNY, SNY, MNTA, MNTA, ONXX, ONXX, AMGN, AMGN, MRK, MRK, CBST, CBST, BIIB, BIIB, SHPG, SHPGBoston Biotech Conferences to host a conference
BD Biotech Conference is being held in Boston on April 2-3.
News For GLW;BIIB;CBST;MRK;AMGN;ONXX;MNTA;SNY;LLY;BAYRY;PFE;GSK;SHPG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 >>
January 27, 2016
08:36 EDTMRKMerck downgraded to Neutral on lack of catalysts at BofA/Merrill
Subscribe for More Information
08:31 EDTMRKMerck says FDA accepts for review BLA for investigational antitoxin
Subscribe for More Information
08:29 EDTMRKMerck downgraded to Neutral from Buy at BofA/Merrill
08:26 EDTBIIBBiogen sees FY16 CapEx $800M-$850M
Subscribe for More Information
08:20 EDTGLWCorning reported strong results, says Bernstein
After Corning's Q4 results beat expectations, Bernstein says that the results were strong. The firm says that the company's guidance was "mixed," but indicates that its display glass business will be strong this year despite a weak start to Q1. Bernstein says that the company's decision to hedge its yen exposure is positive, and it keeps a $26 price target and Outperform rating.
08:07 EDTAMGNAmgen volatility elevated into Q4 and outlook
Subscribe for More Information
07:18 EDTBIIBBiogen says looks to advance several potential breakthrough programs in 2016
Subscribe for More Information
07:17 EDTBIIBBiogen sees FY16 adjusetd EPS $18.30-$18.60, consensus $18.45
Sees FY16 revenue approx. $11.B-$11.3B, consensus $11.29B. &D expense is expected to be approximately 19% to 20% of total revenue. The company plans to continue to invest in a number of R&D programs across its emerging mid- and late-stage pipeline, including aducanumab for Alzheimer's disease, nusinersen for spinal muscular atrophy, raxatrigine for trigeminal neuralgia and amiselimod for inflammatory bowel disease. In 2016, the Company plans to provide one update to its annual financial guidance, which is expected to be provided in connection with its second quarter earnings release.
07:16 EDTBIIBBiogen reports Q4 adjusted EPS $4.50, consensus $4.08
Subscribe for More Information
06:59 EDTBIIBOptions expected to be active: AAPL FB AMZN BIIB GD HES TXT BA UTX X T
Subscribe for More Information
January 26, 2016
15:31 EDTSNYMannKind exploring potential sale, Reuters reports
MannKind (MNKD), whose shares have plunged 40% since Sanofi (SNY) terminated an agreement for the development and commercialization of inhaled insulin drug Afrezza, is now exploring its strategic options, including a potential sale, reported Reuters, citing people familiar with the matter. MannKind shares are up about 20% to 90c in afternoon trading following the report. Reference Link
14:32 EDTBIIBNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's open, with earnings consensus, include Novartis (NVS), consensus $1.18... Boeing (BA), consensus $1.26... United Technologies (UTX), consensus $1.52... Biogen (BIIB), consensus $4.08... EMC (EMC), consensus 65c... General Dynamics (GD), consensus $2.38... Anthem (ANTM), consensus $1.22... Illinois Tool Works (ITW), consensus $1.21... State Street (STT), consensus $1.18... Norfolk Southern (NSC), consensus $1.24... Progressive (PGR), consensus 47c... St. Jude Medical (STJ), consensus $1.01... Rockwell Automation (ROK), consensus $1.33... Textron (TXT), consensus 83c... Hess (HES), consensus ($1.47)... Cliffs Natural (CLF), consensus (26c).
09:32 EDTGLWActive equity options trading on open
Active equity options trading on open: FB PEP NFLX PM GM RMBS MSFT GLW AAPL
09:32 EDTGLWCorning sees gros margin percentages improving year-over-year in 2H16
Subscribe for More Information
09:28 EDTGLWCorning sees Q1 global economic headwinds to continue in Q1
Corning's (GLW) management said that volume in Q1 will reflect the weaker retail market. Management said that Q1 will be the weakest quarter in the fiscal year. The company sees glass market volumes to be down mid-to-high single digits. The company expects glass market volume growth to begin in Q2. The company sees prices to decline moderately sequentially in Q1. The company sees its optical communications segment up low-to-mid single digits. The company sees environmental sales down approximately 10% in Q1. Corning expects its special materials segment sales down mid teens. The company expects its life sciences sales up low-single digits. Dow Corning, Corning's joint venture with Dow Chemical (DD), equity earnings are expected to be approximately $45M in Q1. Corning sees core gross margin approximately 41% of sales in Q1. Guidance provided during Q4 earnings conference call.
07:47 EDTBIIBBiogen volatility elevated into Q4 and outlook
Biogen January weekly call option implied volatility is at 87, February is at 45; compared to its 52-week range of 23 to 58, suggesting large near term price movement into the expected release of Q4 results on January 27.
06:55 EDTGLWCorning expects Q1 to be weakest of 2016, growth to recover in Q2-Q4
Subscribe for More Information
06:53 EDTGLWCorning reports Q4 Display Technologies core sales $903M
Subscribe for More Information
06:52 EDTGLWCorning reports Q4 core EPS 34c, consensus 32c
Subscribe for More Information
06:33 EDTBAYRYImmunoGen earns milestone payment from Bayer related to BAY 94-9343
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use